Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Recognition of emotional facial expressions in anxious and nonanxious depression.

Berg HE, Ballard ED, Luckenbaugh DA, Nugent AC, Ionescu DF, Zarate CA Jr.

Compr Psychiatry. 2016 Oct;70:1-8. doi: 10.1016/j.comppsych.2016.06.007. Epub 2016 Jun 14.

PMID:
27624417
2.

Investigating the nature of co-occurring depression and anxiety: Comparing diagnostic and dimensional research approaches.

Kircanski K, LeMoult J, Ordaz S, Gotlib IH.

J Affect Disord. 2017 Jul;216:123-135. doi: 10.1016/j.jad.2016.08.006. Epub 2016 Aug 13. Review.

PMID:
27554605
3.

Comorbid anxiety increases cognitive control activation in Major Depressive Disorder.

Crane NA, Jenkins LM, Dion C, Meyers KK, Weldon AL, Gabriel LB, Walker SJ, Hsu DT, Noll DC, Klumpp H, Phan KL, Zubieta JK, Langenecker SA.

Depress Anxiety. 2016 Oct;33(10):967-977. doi: 10.1002/da.22541. Epub 2016 Jul 25.

PMID:
27454009
4.

Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder.

Baek JH, Kim HJ, Fava M, Mischoulon D, Papakostas GI, Nierenberg A, Heo JY, Jeon HJ.

Psychiatry Investig. 2016 May;13(3):321-6. doi: 10.4306/pi.2016.13.3.321. Epub 2016 May 18.

5.

The underlying neurobiology of key functional domains in young people with mood and anxiety disorders: a systematic review.

Iorfino F, Hickie IB, Lee RS, Lagopoulos J, Hermens DF.

BMC Psychiatry. 2016 May 23;16:156. doi: 10.1186/s12888-016-0852-3.

6.

Cyclooxygenase-2 inhibition reduces stress-induced affective pathology.

Gamble-George JC, Baldi R, Halladay L, Kocharian A, Hartley N, Silva CG, Roberts H, Haymer A, Marnett LJ, Holmes A, Patel S.

Elife. 2016 May 10;5. pii: e14137. doi: 10.7554/eLife.14137.

7.

Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice.

Dell'Osso B, Albert U, Atti AR, Carmassi C, Carrà G, Cosci F, Del Vecchio V, Di Nicola M, Ferrari S, Goracci A, Iasevoli F, Luciano M, Martinotti G, Nanni MG, Nivoli A, Pinna F, Poloni N, Pompili M, Sampogna G, Tarricone I, Tosato S, Volpe U, Fiorillo A.

Neuropsychiatr Dis Treat. 2015 Jul 30;11:1885-909. doi: 10.2147/NDT.S83130. eCollection 2015. Review.

8.

The association of depression and anxiety with pain: a study from NESDA.

de Heer EW, Gerrits MM, Beekman AT, Dekker J, van Marwijk HW, de Waal MW, Spinhoven P, Penninx BW, van der Feltz-Cornelis CM.

PLoS One. 2014 Oct 15;9(10):e106907. doi: 10.1371/journal.pone.0106907. eCollection 2014. Erratum in: PLoS One. 2014;9(12):e115077.

9.

Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.

Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, Brutsché NE, Ameli R, Furey ML, Zarate CA Jr.

J Psychiatr Res. 2014 Nov;58:161-6. doi: 10.1016/j.jpsychires.2014.07.027. Epub 2014 Aug 12.

10.

Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder.

Thase ME, Chen D, Edwards J, Ruth A.

Int Clin Psychopharmacol. 2014 Nov;29(6):351-6. doi: 10.1097/YIC.0000000000000045.

11.

Clinical relevance of vilazodone treatment in patients with major depressive disorder: categorical improvement in symptoms.

Culpepper L, Mathews M, Ghori R, Edwards J.

Prim Care Companion CNS Disord. 2014;16(1). pii: PCC.13m01571. doi: 10.4088/PCC.13m01571. Epub 2014 Jan 30.

12.

Defining anxious depression: a review of the literature.

Ionescu DF, Niciu MJ, Henter ID, Zarate CA.

CNS Spectr. 2013 Oct;18(5):252-60. doi: 10.1017/S1092852913000114. Epub 2013 Mar 14. Review.

13.

Neurobiology of anxious depression: a review.

Ionescu DF, Niciu MJ, Mathews DC, Richards EM, Zarate CA Jr.

Depress Anxiety. 2013 Apr;30(4):374-85. doi: 10.1002/da.22095. Epub 2013 Mar 11. Review.

14.
15.

Outcomes of acute phase cognitive therapy in outpatients with anxious versus nonanxious depression.

Smits JA, Minhajuddin A, Thase ME, Jarrett RB.

Psychother Psychosom. 2012;81(3):153-60. doi: 10.1159/000334909. Epub 2012 Mar 3.

16.

What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?

Gollan JK, Fava M, Kurian B, Wisniewski SR, Rush AJ, Daly E, Miyahara S, Trivedi MH.

Depress Anxiety. 2012 Feb;29(2):94-101. doi: 10.1002/da.20917. Epub 2011 Dec 6.

17.

Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains.

Benton CS, Miller BH, Skwerer S, Suzuki O, Schultz LE, Cameron MD, Marron JS, Pletcher MT, Wiltshire T.

Psychopharmacology (Berl). 2012 May;221(2):297-315. doi: 10.1007/s00213-011-2574-z. Epub 2011 Nov 24.

18.

Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram.

Fiedorowicz JG, Hale N, Spector AA, Coryell WH.

Ann Clin Psychiatry. 2010 Aug;22(3):157-63.

19.

The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication.

Fava M, Hwang I, Rush AJ, Sampson N, Walters EE, Kessler RC.

Mol Psychiatry. 2010 Aug;15(8):856-67. doi: 10.1038/mp.2009.20. Epub 2009 Mar 10.

20.

Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder.

Perlis RH, Fava M, Trivedi MH, Alpert J, Luther JF, Wisniewski SR, Rush AJ.

Acta Psychiatr Scand. 2009 Apr;119(4):282-9. doi: 10.1111/j.1600-0447.2008.01298.x. Epub 2009 Feb 5.

Supplemental Content

Support Center